Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline

Tyler J. Bussian, Asef Aziz, Charlton F. Meyer, Barbara L. Swenson, Jan Van Deursen, Darren J Baker

Research output: Contribution to journalLetter

63 Citations (Scopus)

Abstract

Cellular senescence, which is characterized by an irreversible cell-cycle arrest1 accompanied by a distinctive secretory phenotype2, can be induced through various intracellular and extracellular factors. Senescent cells that express the cell cycle inhibitory protein p16INK4A have been found to actively drive naturally occurring age-related tissue deterioration3,4 and contribute to several diseases associated with ageing, including atherosclerosis5 and osteoarthritis6. Various markers of senescence have been observed in patients with neurodegenerative diseases7–9; however, a role for senescent cells in the aetiology of these pathologies is unknown. Here we show a causal link between the accumulation of senescent cells and cognition-associated neuronal loss. We found that the MAPTP301SPS19 mouse model of tau-dependent neurodegenerative disease10 accumulates p16INK4A-positive senescent astrocytes and microglia. Clearance of these cells as they arise using INK-ATTAC transgenic mice prevents gliosis, hyperphosphorylation of both soluble and insoluble tau leading to neurofibrillary tangle deposition, and degeneration of cortical and hippocampal neurons, thus preserving cognitive function. Pharmacological intervention with a first-generation senolytic modulates tau aggregation. Collectively, these results show that senescent cells have a role in the initiation and progression of tau-mediated disease, and suggest that targeting senescent cells may provide a therapeutic avenue for the treatment of these pathologies.

Original languageEnglish (US)
Pages (from-to)578-582
Number of pages5
JournalNature
Volume562
Issue number7728
DOIs
StatePublished - Oct 25 2018

Fingerprint

Neuroglia
Pathology
Cognition
Cell Cycle Proteins
Neurofibrillary Tangles
Gliosis
Cell Aging
Microglia
Astrocytes
Transgenic Mice
Cognitive Dysfunction
Cell Cycle
Pharmacology
Neurons
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. / Bussian, Tyler J.; Aziz, Asef; Meyer, Charlton F.; Swenson, Barbara L.; Van Deursen, Jan; Baker, Darren J.

In: Nature, Vol. 562, No. 7728, 25.10.2018, p. 578-582.

Research output: Contribution to journalLetter

Bussian, Tyler J. ; Aziz, Asef ; Meyer, Charlton F. ; Swenson, Barbara L. ; Van Deursen, Jan ; Baker, Darren J. / Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. In: Nature. 2018 ; Vol. 562, No. 7728. pp. 578-582.
@article{4b51f62bbe874c9199411ccc8cfcfd67,
title = "Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline",
abstract = "Cellular senescence, which is characterized by an irreversible cell-cycle arrest1 accompanied by a distinctive secretory phenotype2, can be induced through various intracellular and extracellular factors. Senescent cells that express the cell cycle inhibitory protein p16INK4A have been found to actively drive naturally occurring age-related tissue deterioration3,4 and contribute to several diseases associated with ageing, including atherosclerosis5 and osteoarthritis6. Various markers of senescence have been observed in patients with neurodegenerative diseases7–9; however, a role for senescent cells in the aetiology of these pathologies is unknown. Here we show a causal link between the accumulation of senescent cells and cognition-associated neuronal loss. We found that the MAPTP301SPS19 mouse model of tau-dependent neurodegenerative disease10 accumulates p16INK4A-positive senescent astrocytes and microglia. Clearance of these cells as they arise using INK-ATTAC transgenic mice prevents gliosis, hyperphosphorylation of both soluble and insoluble tau leading to neurofibrillary tangle deposition, and degeneration of cortical and hippocampal neurons, thus preserving cognitive function. Pharmacological intervention with a first-generation senolytic modulates tau aggregation. Collectively, these results show that senescent cells have a role in the initiation and progression of tau-mediated disease, and suggest that targeting senescent cells may provide a therapeutic avenue for the treatment of these pathologies.",
author = "Bussian, {Tyler J.} and Asef Aziz and Meyer, {Charlton F.} and Swenson, {Barbara L.} and {Van Deursen}, Jan and Baker, {Darren J}",
year = "2018",
month = "10",
day = "25",
doi = "10.1038/s41586-018-0543-y",
language = "English (US)",
volume = "562",
pages = "578--582",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7728",

}

TY - JOUR

T1 - Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline

AU - Bussian, Tyler J.

AU - Aziz, Asef

AU - Meyer, Charlton F.

AU - Swenson, Barbara L.

AU - Van Deursen, Jan

AU - Baker, Darren J

PY - 2018/10/25

Y1 - 2018/10/25

N2 - Cellular senescence, which is characterized by an irreversible cell-cycle arrest1 accompanied by a distinctive secretory phenotype2, can be induced through various intracellular and extracellular factors. Senescent cells that express the cell cycle inhibitory protein p16INK4A have been found to actively drive naturally occurring age-related tissue deterioration3,4 and contribute to several diseases associated with ageing, including atherosclerosis5 and osteoarthritis6. Various markers of senescence have been observed in patients with neurodegenerative diseases7–9; however, a role for senescent cells in the aetiology of these pathologies is unknown. Here we show a causal link between the accumulation of senescent cells and cognition-associated neuronal loss. We found that the MAPTP301SPS19 mouse model of tau-dependent neurodegenerative disease10 accumulates p16INK4A-positive senescent astrocytes and microglia. Clearance of these cells as they arise using INK-ATTAC transgenic mice prevents gliosis, hyperphosphorylation of both soluble and insoluble tau leading to neurofibrillary tangle deposition, and degeneration of cortical and hippocampal neurons, thus preserving cognitive function. Pharmacological intervention with a first-generation senolytic modulates tau aggregation. Collectively, these results show that senescent cells have a role in the initiation and progression of tau-mediated disease, and suggest that targeting senescent cells may provide a therapeutic avenue for the treatment of these pathologies.

AB - Cellular senescence, which is characterized by an irreversible cell-cycle arrest1 accompanied by a distinctive secretory phenotype2, can be induced through various intracellular and extracellular factors. Senescent cells that express the cell cycle inhibitory protein p16INK4A have been found to actively drive naturally occurring age-related tissue deterioration3,4 and contribute to several diseases associated with ageing, including atherosclerosis5 and osteoarthritis6. Various markers of senescence have been observed in patients with neurodegenerative diseases7–9; however, a role for senescent cells in the aetiology of these pathologies is unknown. Here we show a causal link between the accumulation of senescent cells and cognition-associated neuronal loss. We found that the MAPTP301SPS19 mouse model of tau-dependent neurodegenerative disease10 accumulates p16INK4A-positive senescent astrocytes and microglia. Clearance of these cells as they arise using INK-ATTAC transgenic mice prevents gliosis, hyperphosphorylation of both soluble and insoluble tau leading to neurofibrillary tangle deposition, and degeneration of cortical and hippocampal neurons, thus preserving cognitive function. Pharmacological intervention with a first-generation senolytic modulates tau aggregation. Collectively, these results show that senescent cells have a role in the initiation and progression of tau-mediated disease, and suggest that targeting senescent cells may provide a therapeutic avenue for the treatment of these pathologies.

UR - http://www.scopus.com/inward/record.url?scp=85055427189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055427189&partnerID=8YFLogxK

U2 - 10.1038/s41586-018-0543-y

DO - 10.1038/s41586-018-0543-y

M3 - Letter

VL - 562

SP - 578

EP - 582

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7728

ER -